Translational Molecular Imaging of Prostate Cancer

Research output: Contribution to journalReview article

Abstract

Prostate cancer is a heterogeneous disease, and its management is now evolving to become more personalized and to incorporate new targeted therapy. With these new changes comes a demand for molecular imaging techniques that not only detect disease but also assess biology and treatment response. This review article summarizes the current status of molecular imaging in prostate cancer (e.g. 99m Tc bone scintigraphy and 18 F-fluorodeoxyglucose positron-emission tomography), with emphasis on emerging clinical and preclinical imaging agents, and their mechanism and clinical application. Emerging agents at different stages of clinical use include radiolabeled analogs of lipid, amino acid, and nucleoside metabolites, and agents more specifically targeting prostate cancer biomarkers, including androgen receptor, prostate-specific membrane antigen, and others. We also emphasize new techniques and targeted contrast agents for magnetic resonance imaging and spectroscopy. For all of these imaging techniques, a growing and important unfulfilled need is for well-designed prospective clinical trials which establish clear indications with clinical benefit in prostate cancer.

Original languageEnglish (US)
Pages (from-to)216-226
Number of pages11
JournalCurrent Radiology Reports
Volume1
Issue number3
DOIs
StatePublished - Sep 14 2013

Keywords

  • Androgen receptor
  • Magnetic resonance imaging
  • Molecular imaging
  • Positron-emission tomography
  • Prostate cancer
  • Prostate-specific membrane antigen
  • Single-photon-emission computed tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Translational Molecular Imaging of Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this